Talking Urology Podcast: Recent Episodes
Talking Urology
Damien Bolton & Andrew Weickhardt discuss ‘The COVID conundrum: loss and lessons learned.
Prof Thomas Powles joins Talking Urology to discuss the new measures of success with IO agents.
A/Prof Shariat is currently professor and chairman of the department of urology, Medical University of Vienna General Hospital, Austria.
He is also adjunct professor of urology and medical oncology at Weill Cornell Medical Center, New York, and adjunct professor or urology at the University of Texas Southwestern Medical Center, Dallas, USA.
Prof Van Poppel is the Chairman of the Department of Urology at the University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium. He is a Board Member of the European Association of Urology (EAU), the European Society of Surgical Oncology and the European Organization for Research and Treatment of Cancer, where he is also Study Coordinator and Treasurer of the Genito-Urinary Group. He is Chairman of the Educational Office of the EAU and Director of the European School of Urology.
Join the star-studded cast of Talking Urology with Neal Shore, Ben Tran and Joseph Ischia as they unearth the mysteries of non-metastatic CRPC
Dr. Klotz is the founding editor of the Canadian Urology Association Journal and is now the Editor Emeritus. He is chairman of the Canadian Urology Research Consortium and is a widely published uro-oncologist with over 300 publications and 4 books.
His main research interest has been prostate cancer and was awarded the Queen’s Jubilee Medal for meritorious public service.
Dr. Lin is Professor and Chief of Urologic Oncology in the Department of Urology and holds the Bridges Endowed Professorship for Prostate Cancer Research at the University of Washington School of Medicine.
Dr. Lin’s major basic/translational research interests are in prostate chemoprevention and molecular/genomic biomarkers for aggressive prostate cancer, and his major clinical research efforts are in prostate cancer active surveillance and novel strategies in high-risk prostate cancer.
Dr. Nitti is a Professor of Urology and OB/GYN, Vice-Chairman of Urology, Director of the Female Pelvic Medicine and Reconstructive Surgery at New York University Langone Medical Center.
A graduate of the University of Medicine and Dentistry of New Jersey, Dr. Nitti completed his urology residency at SUNY Downstate in Brooklyn, NY and his fellowship in Female Urology, Neurourology, and Reconstructive Urology at UCLA. He is a Fellow of the American College of Surgeons and the American Board of Urology.
Dr. Quinn is currently the Medical Director of the Norris Cancer Hospital, the Head of Genitourinary Medical Oncology and Associate Professor of Medicine in the Division of Oncology, Keck School of Medicine, University of Southern California.
He is a medical oncologist and an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics.
Maurizio Brausi discusses his landmark paper on BCG in Intermediate & High-risk Ta, T1 Papillary Ca of the Bladder.
Dr Renu Eapen is a Consultant Urologist in the Genitourinary Oncology service at the Austin Hospital Olivia Newton-John Cancer Centre and the Peter MacCallum Cancer Centre. Dr Eapen undertook research in Female Pelvic Medicine and Reconstructive Surgery at University of Texas Southwestern Dallas. She went on to complete a subspecialty Fellowship at the University of Toronto, Canada and subsequently obtained her robotics and uro-oncology Fellowship at University of California, San Francisco. She is currently undertaking her PhD at the University of Melbourne. Axel Merseburger is Professor of Urology and Chairman of the Department of Urology at University Hospital Schleswig Holstein, Campus Lübeck, in Lübeck, Germany. He was appointed Associate Professor, in 2009, and Professor, in 2012, at Hannover Medical School. He is Principal Investigator for multiple phase 2 and phase 3 clinical trials. Prof. Merseburger is as an advisor for the European Association of Urology (EAU) Guidelines Group for Renal Cancer and has previously served as Chairman of the EAU Guidelines Group for Lasers and Technologies. Prof. Merseburger acts as a reviewer and editorial board member for several urology and oncology indexed journals, is Associate Editor of the World Journal of Urology, and is Editor-in-Chief of European Oncology & Haematology.
Joseph Ischia is outnumbered by exercise physiologists. Listen in as he co-hosts with Dale Ischia, Ashley Bigaran and special guest Eva Zopf. Dale Ischia is an Accredited Exercise Physiologist from Melbourne with over 20 years clinical experience. She founded ‘Moving Beyond Cancer’, an exercise physiology program dedicated to improving the lives of people with a cancer diagnosis through appropriately prescribed exercise. Ashley is an AEP and PhD candidate with a developing reputation as a junior researcher. She has over eight years’ experience as an AEP and has been employed in leading public and private health settings, high performance teams and university institutions. Ashley is the Co-Chair of the ESSA Victoria State Chapter and consults clinically at the Baker Institute’. Special guest, Dr Eva Zopf, is an exercise physiologist and completed her PhD in Exercise Oncology at the German Sport University in Cologne in Germany, she did a postdoctoral research fellowship at Edith Cowan University in Perth and is now a key member of the Exercise Oncology team at the Australian Catholic University.
Dr Estella graduated from the University of Queensland (Medicine) in 1994 with the prize in medicine therapeutics. His endocrine training commenced in Brisbane at the Princess Alexandra Hospital and the Greenslopes hospital. He has undertaken further studies and a PhD in the area of Type 1 diabetes. Dr Estella has authored many articles and medical papers and is dedicated in keeping up to date with the latest medical developments.
Professor Suzanne Chambers is the dean of the faculty of health at University of technology Sydney and previously, the director of the Menzies Institute at Griffith University. She is a health psychologist and registered nurse who has worked as a practitioner and researcher in psychological support for people with cancer for over 25 years. Professor Chambers was made an Officer of the Order of Australia in the 2018 Queen’s Birthday Honours for distinguished service to medical research, particularly in the area of psycho-oncology, and to community health through patient care strategies to assist men with prostate cancer.
She has published extensively on the psychological effects of cancer with over 7000 citations of her work from leading journals in the field. Professor Chambers is currently chair of the Quality of Life and Supportive Care Committee for the Australian and New Zealand Urogenital and Prostate Cancer Trials Group and is also affiliated with Cancer Council Queensland and the Prostate Cancer Foundation of Australia. She holds adjunct professorships at Edith Cowan University, the University of Queensland and University of Southern Queensland.
Hosts Joseph Ischia and Victoria Cullen, along with special guest Richard Wassersug, discuss the impact of ADT on the sex life of patients with prostate cancer. Victoria Cullen is a Sexuality Educator and PhD candidate at RMIT University. She obtained her Bachelor’s degree and Masters in Cognitive Psychology from University College London. In 2015, Victoria co-founded the world's first sex toy design course in an academic setting at RMIT University and in 2017, she partnered with Urology Surgeon, Professor Declan Murphy, to deliver complimentary consultations to prostatectomy patients. She offers free online resources for sexual recovery post prostate cancer treatment through her website www.atouchysubject.com.
Richard Wassersug is a research scientist and also a prostate cancer patient, based in Vancouver, Canada, where he holds the position of Honorary Professor in the Faculty of Medicine at the University of British Columbia. He has authored or coauthored over 300 academic papers in fields as diverse as human sexuality and amphibian biology. However, a major focus of his research for the last decade has been on the psychology of androgen deprivation. An over-arching goal of Dr.Wassersug’s work is to develop ways to help men and their partners recognize and overcome the side effect burden from androgen deprivation therapy, which is the primary treatment for systemic prostate cancer. This research led to the 2014 book “Androgen Deprivation Therapy: An essential guide for prostate cancer patients and their loved ones” for which he is the lead author. A 2ndedition was published in 2018, and the two editions together have sold ~70,000 copies. Dr. Wassersug is a Co-lead for Canada's Androgen Deprivation Therapy Educational Program.
So You’re Gonna . . . do a TURBT with Prof Lukas Lusuardi, Joseph Ischia & Nicholas Campbell.
In this ANZUP conference highlight, Henry Woo chats to Kelly Parsons Professor of Urology, UC San Diego. He is a clinician, a clinical triallist, and an author of wonderful and sometimes saucy medical fiction. Henry and Kelly explore the 5 key biases of urologists and surgeons, and why urologists need to get involved in clinical trial teams.
In this ANZUP conference highlight, Andrew Weickhardt chats with Betsy Plimack, Chief of the Division of Genitourinary Medical Oncology, Fox Chase Cancer Centre in the US. She talks about the future potential role of genetic mutations in urothelial cancer: can they predict response to treatments or even decide which treatments you should use? They also discuss the use of the new immuno-oncology agents in metastatic kidney cancer: what are the second line options, and how do we measure success of treatments- keep a close ear out for the emerging concept of treatment free survival as the yard stick for the immune-oncology agents.
In this ANZUP conference highlight, Andrew Weickhardt chats with Australia’s very own Ian Davis about ANZUP’s successful world leading phase 3 study, ENZAMET. Ian outlines ENZAMET for men with newly diagnosed metastatic hormone naïve prostate cancer and how it differs from the other trials involving second line anti-androgens in this space. Ian also discusses how you might decide between the myriad of treatment options that have now shown effect in the upfront hormone naïve metastatic setting.
In this ANZUP conference highlight, Kath Schubach chats to Catherine Paterson from the Department of Nursing and Midwifery, University of Canberra about some of the key messages from the nursing program at ANZUP how to improve the supportive care needs of patients with urological cancers.
In this ANZUP conference highlight, this year’s convenor David Pryor chats to Phuoc Tran, a radiation oncologist from John Hopkins, about his success with the Oriel trial of stereotactic radiation for patients with oligometastatic prostate cancer.
In this ANZUP conference highlight, Craig Gedye chats to Carole Harris, Patti Bastik & Antoinette Fontela, the investigators for the KEYPAD trial. They chat about what it is like to be involved in a clinical trial for the doctor and the patients, the barriers faced to running a successful clinical trial, the KEYPAD study investigating the addition of immuno-oncology agents plus denosumab, and the techniques they have used to improve the success of their trials.
Haryana Dhillon & Jasmine Yee talk about the beneficial role of exercise in patients with a cancer diagnosis with a particular focus on those with advanced cancers.
Prof Ian Davis chats with Prof David Quinn about the latest research for metastatic kidney cancer and the changes we’ve seen in first line treatments.
Dr Alison Birtle & Prof Ian Davis discuss the development and execution of the phase 3 POUT trial which has set the new standard of the benefit of adjuvant chemotherapy in men with locally advanced upper tract urothelial cancer after nephro-ureterectomy.
Prof Francesco Montorsi talks with Joseph Ischia & Nathan Lawrentshuk about the long and short of penile rehabilitation.
Talking Urology Series 2 Episode 1 – Join Joseph and Nathan as they talk with John Yaxley and discuss if robotic surgery achieves better outcomes than open surgery when it comes to radical prostatectomy.
Talking Urology conducted a series of live recordings at USANZ 2019 conference in Brisbane.
Joseph Ischia discusses a range of topics with the following distinguished luminaries in the field of urology:
Prof Axel Heidenreich, Dr Peter Burke, Dr Ian Vela, Dr Guido Barbagli, Prof Peter Gilling, Dr Jo Semins, Prof Scott Eggener, Dr Tim Donahue, Prof Alex Mottrie, A/Prof Peter Chin, Prof David Nicol, Prof James N’Dow & Prof Andrea Tubaro
This Talking Urology conference summary is supported by Ipsen.
A/Professor Joseph Ischia and co-host Dr Rachel Esler talk with Prof Claus Roehrborn about the key literature and take home points for starting BPH patients on alpha-blocker therapy.
A/Prof Andrew Weickhardt discusses the CARMENA trial with A/Prof Laurence Albiges and Dr Monty Pal. Can we take away any positives from this negative trial?
A/Prof Laurence Albiges and Dr Monty Pal discuss the changing landscape and biomarkers in metastatic renal cell carcinoma with A/Prof Andrew Weickhardt.
Assistant Prof Angie Smith discusses the four types of BCG failure and subsequent management in patients with non-muscle invasive bladder cancer.
Dr Tombal explores the future of academic urology. How can we get surgeons back into research?
Prof Chris Sweeney discusses intermittent versus continuous ADT in metastatic hormone sensitive prostate cancer. Can you balance survival and quality of life?
Dr Haryana Dhillon: Are we doing enough to address anxiety and depression in patients with prostate cancer and what can we do about it?
Dr Joseph Ischia chats with ANZUP 2018 Convenor Henry Woo. Enjoy the highlights of the conference through the eyes of the convenor.
As ANZUP celebrates its 10th Anniversary, Prof Ian Davis reflects on how ANZUP brings people together to improve patient outcomes.
Dr Carmel Pezaro talks with Dr Ben Tran about ‘Bringing Data Back’. He’s sexy. He’s funny. You’ll love him.
Dr Niazi discusses prostate oligometastatic targeted therapy in castration resistant prostate cancer.
Dr Joseph Ischia chats with David Pryor, the convenor of the 2019 ANZUP conference in Brisbane July 21-23.
Lisa Horvath discusses her research on how a man's plasma lipid signature can predict prognosis in castration resistant prostate cancer
Lisa Butler discusses her research on identifying drug response biomarkers in prostate cancer
Alex Kutikov discusses his new metric for determining the utility of MRI-US fusion prostate biopsy.
Prue Cormie discusses the multitude of benefits of exercise in men with prostate cancer.
Camille Short discusses her innovative website to support men underoging treatment for metastatic prostate cancer
Silke Gillessen discusses the interesting findings from the Advanced Prostate Cancer Consensus Conference in St Gallen.
Michael Hofman discusses the new ANZUP/PCFA trial investigating therapeutic Lutetium (Lu-177) PSMA for men with advanced mCRPC.
Bente Thoft Jensen discusses the advancements in prehabiliatation prior to radical cystectomy.
Dennis Taaffe discusses the RADAR trial investigating the important benefits of exercise in men with prostate cancer
David Quinn discusses the KEYNOTE-045 trial on the benefits of pembrolizumab in second line treatment of advanced bladder cancer
Peter Black discusses the dizzying array of new treamtment options on the horizon for advanced bladder cancer
Renea Taylor discusses her research on the poor prognosis associated with BRCA 2 mutation prostate cancer
Alex Kutikov discusses predictors of pT0 bladder cancer after neoadjuvant chemotherapy; can we avoid cystectomy in these patients?
Matthew Roberts discusses the role of seminal plasma (ejaculate) for monitoring men on active surveillance for prostate cancer
Ada Cheung discusses the often missed diagnosis of hypogonadism in men who have had treatment for testicular cancer.
Bill Catalona gave the annual Patrick C Walsh lecture and discusses the 3 big wins in improving prostate cancer outcomes in the PSA era.
Declan Murphy invites you to the 19th Asia-Pacific Prostate Cancer Conference in Brisbane next year 22nd-25th August 2018.
Victoria Cullen's PhD involves sex toy design. She discusses ways of innovating your sex life after treatment for prostate cancer.
Chris Coombes discusses his exciting preliminary results of femoral nerve grafting to treat erectile dysfunction after radical prostatectomy.
Carmel Pezaro discusses the ultimate causes of death in men with advanced prostate cancer: what actually kills them?
Brian Chapin asks if we might be too enthusiastic treating the prostate in men with metastatic disease.
Ben Challacombe discusses how the BAUS National Prostatectomy Audit has tracked improvements in prostate cancer care for UK men.
Mark Emberton discusses the PROMIS study and the role of MRI in prostate cancer diagnosis and active surveillance
Chris Nelson discusses the main reason why relationships suffer after treatment for prostate cancer.
Nick James discusses the two latest outcomes from STAMPEDE: the beneifts of radiation, and upfront abiraterone.
David Penson discusses patient reported outcomes after treatment for localised prostate cancer: are they as good as we would like them to be?
Cora Sternberg discusses prostate cancer heterogeneity and the exciting potential of molecular classification
Herbert Lepor discusses the good news on LUTS and sexual dysfunction following radical prostatectomy: the long game.
Jonathan Epstein discusses the critical role of pathological grading in determining men suitable active surveillance.
Peter Black discusses lessons learned from immunotherapy in bladder cancer and what we might need to look out for in prostate cancer.
Chris Sweeney discusses which is best? Abiraterone vs docetaxal with ADT for hormone naïve metastatic prostate cancer
Chris Sweeney discusses upfront combination therapy and immunotherapy in men with metastatic prostate cancer
Piet Ost discusses the STOMP trial and the benefits of metastasis directed therapy in oligometastatic disease
John Oliffe discusses the factors contributing to depression and suicidality in men with prostate cancer
A/Prof Nathan Lawrentschuk, USANZ 2017 convener, host of Talking Urology & Urological Surgeon & Urologic Oncologist.
Joseph discusses with Nathan highlights of USANZ 2017 and the emerging themes.
Talking Urology is proudly supported by Ipsen.
A/Prof Shankar Siva, Radiation Oncologist & NHMRC fellow at the Peter MacCallum Cancer Centre, Melbourne.
Shankar argues the case for metastasis directed therapy with Joseph in oligometastatic disease.
Talking Urology is proudly supported by Ipsen.
Sandra Warden, Nurse Practitioner, Queensland.
Boston Scientific Diamond Scholarship winner
Talking Urology is proudly supported by Ipsen.
Richard Grills, Urological Surgeon, MBBS, FRACS Director - Urolological Surgery, Barwon Health, University Hospital Geelong
Richard is the winner of the Abbvie Platinum trophy, Research Innovation.
Talking Urology is proudly supported by Ipsen.
Kath Schubach, Nurse Practitioner & vice president ANZUNS, Melbourne
Joseph and Kath discuss the highlights from ANZUNS
Talking Urology is proudly supported by Ipsen
Dr Marlon Perera, Urology trainee, Queensland Health.
Marlon is the Villis Marshall prize winner, for his research presentation “The renoprotective role of zinc preconditioning against radiographic contrast-media induced nephrotoxity".
Talking Urology is proudly supported by Ipsen
Cara Webb, Urology Clinical Nurse Consultant, Austin Health, Melbourne
Cara was the Best Poster winner for her study, ‘an evaluation of a nurse-led post operative outpatient clinic’.
Talking Urology is proudly supported by Ipsen
David Gray, NP,BN, MN (Urology & Continence), Urology Nurse Practitioner, Australian Prostate Cancer Research Centre, Melbourne.
ANZUNS innovative paper award winner for the fellowship run at the Australian Prostate Research Centre.
Talking Urology is proudly supported by Ipsen.
Laurence Klotz, MD is Chief of Urology at Sunnybrook Health Sciences Centre & Professor of Surgery at the University of Toronto.
Joseph & Laurie discuss surgery vs radiation which was one of the more controversial talks.
Talking Urology is proudly supported by Ipsen.
Talking Urology conducted a series of live recordings at USANZ 2017 conference in Canberra. Part 3 of the USANZ 2017 Conference Summary sees Melbourne-based urologist Dr Joseph Ischia discussing a range of topics with the following thought leaders in the field of urology:
A/Prof Shankar Shiva, Dr Laurence Klotz, A/Prof Nathan Lawrentschuk, Dr Marlon Perera, Richard Grills, Kath Schubach, Sandra Warden, David Gray, Cara Webb
Talking Urology is supported by Ipsen
Mark Frydenberg AM @mfrydenberg is Past President of USANZ, a Uro-oncologist with Australian Urology Associates and Professor, Department of Surgery, Monash University.
Professor Frydenberg gives his presidential insights.
Associate Professor Declan G Murphy @declangmurphy is a Consultant Urological Surgeon at Royal Melbourne Hospital & Director of Robotic Surgery at The Peter MacCallum Cancer Centre.
Declan Murphy discusses trials & tribulations of robotic surgery.
Professor Damian Bolton @damian_bolton is an Associate Professor at the University of Melbourne, Department or Surgery and head of the Urology unit at the Austin Hospital in Melbourne.
Damien discusses Olivier Traxer's talk on optimising the use of holmium laser with Dr Joseph Ischia.
Professor Christopher Chapple is a Consultant Urological Surgeon at Sheffield Teaching Hospitals and Visiting Professor at Sheffield Hallam University.
Professor Chris Chapple discusses the underactive bladder.
Dr Henry Woo @DrHWoo is Professor of Surgery & Discipline Head at the Sydney Adventist Hospital Clinical School, and Professor of Robotic Cancer Surgery & Director of Uro-Oncology at Chris O’Brien Lifehouse.
Professor Henry Woo gives an Australian perspective on minimally invasive treatments for Benign Prostatic Hyperplasia.
Professor Robert Alexander (‘Frank’) Gardiner AM is an academic urologist with the University of Queensland Centre for Clinical Research at Royal Brisbane & Women’s Hospital where he is appointed as Consultant Urologist.
Professor Frank Gardiner shares his insights into the trials & tribulations of robotic surgery trials.
Dr Ian Vela is a Urologic Oncologist in the Department of Urology Princess Alexandra Hospital in Brisbane, and a Senior Research Fellow at the Australian Prostate Cancer Research Centre.
Dr Ian Vela gives an Australian perspective on neoadjuvant and adjuvant treatments for high risk prostate cancer.
James A. Eastham, MD, is Professor and Chief of the Urology Service, Department of Surgery, Memorial Sloan- Kettering Cancer Center in New York. Dr James Eastham discusses neoadjuvant & adjuvant treatments for radical prostatectomy.
Dr Johan Gani is a fellow of the Royal Australasian College of Surgeons and a member of the Urological Society of Australia and New Zealand, with public appointments at the Austin and Western Hospitals.
Dr Johan Gani discusses detrusor underactivity with Joseph.
Dr Kevin McVary, MD, FACS - Professor, Department of Surgery, Chair, Division of Urology, Southern Illinois University School of Medicine.
Joseph Ischia discusses the management of Benign Prostatic Hyperplasia management with Professor Kevin McVary.
Part 2 of the USANZ 2017 Conference Summary contains more of Melbourne-based urologist Dr Joseph Ischia’s discussions from the Canberra meeting. Hear Dr Ischia talking about a range of topics with the following leading lights in the field of urology:
Prof Kevin McVary; Dr Johan Gani; Prof James Eastham; Dr Ian Vela; Prof Frank Gardiner; Prof Henry Woo; Prof Chris Chapple; Prof Damian Bolton; Prof Declan Murphy; Prof Mark Frydenberg.
Talking Urology conducted a series of live recordings at the recent USANZ 2017 Conference in Canberra. Part 1 of the USANZ 2017 Conference Summary sees Melbourne-based urologist Dr Joseph Ischia discussing a range of topics with the following leading lights in the field of urology:
Dr Laurence Klotz; Dr Maria Ribal; Dr Shomik Sengupta; Dr Stephen Boorjian; Dr Morgan Pokorny; Dr John Davis; Dr Laurence Levine; Dr Curtis Nickel.
Laurence Klotz, MD is Chief of Urology at Sunnybrook Health Sciences Centre and Professor of Surgery at the University of Toronto.
Laurie outlines his 20-year experience of active surveillance and how they have tightened up the criteria around Gleason 3 + 4 cancers.
Morgan Pokorny holds a VMO appointment at Redcliffe Hospital and consults at the Wesley Medical Centre in Brisbane.
Dr Morgan Pokorny discussed pelvic lymph node dissection for prostate cancer with Dr Joseph Ischia.
Maria J Ribal is Head of the Uro-Oncology Unit, Hospital Clinic, University of Barcelona.
Maria discusses the EAU guidelines for the management of muscle invasive bladder cancer. Listen to her thoughts on the role of nephrostomy for the obstructed kidney.
John W. Davis, MD is Associate Professor and Director of the Urosurgical Prostate Program, Department of Urology, The University of Texas MD Anderson Cancer Center.
John gave the BJUI lecture discussing the role of prostate cancer genetics and the role of the genetic tests that are currently available.
Stephen Boorjian, MD is Professor of Urology at the Mayo Clinic in Rochester, Minnesota.
Dr Ischia talks to Dr Stephen Boorjian about the role of pelvic lymph node dissection with radical prostatectomy.
Associate Professor Sengupta was Scientific Program Director of USANZ 2017. He is a practicing urologist and Director of Training and Research at Austin Health, Heidelberg. Shomik highlights the key goals of management of muscle invasive bladder cancer in an Australian setting.
Laurence A. Levine, MD is a Professor of Urology in the Department of Urology at Rush University Medical Center in Chicago.
Dr Laurence Levine provides an update on treatment options for peyronies disease.
Dr. J. Curtis Nickel, MD is a Professor of Urology at Queen's University in Kingston, Ontario, Canada. Dr Curtis Nickel shares his ground breaking research on the urinary micro biome & its effect on pelvic pain.
Talking Urology Ep. 5 M.D Laurence Klotz. Nadir Testosterone with ADT for Localized Prostate Ca
Join Joseph and Nathan as they discuss the landmark papers that guide your practice everyday.
Guest: A/Prof Shahrokh Shariat